This is an old revision of this page, as edited by Dclutz (talk | contribs) at 03:39, 1 June 2013. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 03:39, 1 June 2013 by Dclutz (talk | contribs)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) | |
| Company type | Public |
|---|---|
| Traded as | Nasdaq: ANTH |
| Industry | Pharmaceuticals |
| Founded | 2004 |
| Headquarters | Hayward, California, U.S. |
| Key people | Paul F. Truex (President and CEO) |
| Website | Anthera.com |
Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat autoimmune diseases. Anthera's Phase 3 development product candidate, blisibimod, targets elevated levels of B-cell activating factor, or BAFF, which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus, or lupus, Immunoglobin A nephropathy, lupus nephritis, vasculitis, rheumatoid arthritis, idiopathic thrombocytopenia purpura, and others.
Product Candidates
- Blisibimod, an investigational anti-BAFF molecule in Phase III trails for the treatment of systemic lupus erythematosus and Phase II trials for the treatment of IgA nephropathy.
References
- . U.S. Securities and Exchange Commission. March 26, 2012 = Form 10-K, Anthera Pharmaceuticals, Inc. http://quote.morningstar.com/stock-filing/Annual-Report/2012/12/31/t.aspx?t=XNAS:ANTH&ft=10-K&d=740adeb41b03cbaebf84e0e2480a09c7 = Form 10-K, Anthera Pharmaceuticals, Inc.
{{cite web}}: Check|url=value (help); Missing or empty|title=(help)
